Pompano Beach, FL, Dec. 01, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today that Brant D. Watson, a University of Miami Professor Emeritus, has joined the Company’s Scientific Advisory Board. Dr. Watson, although self-taught in biomedical research, became a faculty member in the Departments of Neurology and Biomedical Engineering at the University of Miami School of Medicine in 1980, and was promoted to full professor in 1998. He holds a B.A. in Physics and Mathematics from Miami University (Ohio) and a Ph.D. in Nuclear Physics from Florida State University in 1970. He is the author of 91 peer-reviewed articles in professional journals, 25 book chapters, and 110 meeting abstracts on a range of topics that include cancer cytology, ophthalmology and, chiefly, cerebrovascular diseases (stroke) and spinal cord injury. The common theme of his work is photochemically-induced free radical chemistry and lipid peroxidation to induce thrombosis of arteries and veins, and dissolution of such thrombi by photophysically induced nitric oxide. He is a named inventor on two U.S. Patents and has another application in development. Dr. Watson’s research was funded by the National Institute of Neurological Diseases and Stroke for 22 years.
“Dr. Watson’s lifetime of work on vascular and neural healing, grounded in physical insight, will be an enormous asset for us as we move forward with our various solutions in stem cells, regenerative medicine and pharmaceuticals,” said Henry Van Vurst, BioStem Technologies’ founder and CEO. “He is the type of world-class scientist that will insure that our proprietary products become leaders in the global marketplace. His main research attitude is to solve problems as they actually appear in human disease (as opposed to how they are often expressed in artificial animal models), based on powerful and unequivocal physical methods.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drives shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.: Phone: (954) 380-8342 Website: http://www.BioStemtech.com Email: info@BioStemtech.com Twitter: @BioStemTech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst info@BioStemtech.com (954) 380-8342
Source:BioStem Technologies, Inc.